European Investment Bank

Orano is a leading global company based in Courbevoie, France, specializing in nuclear power and renewable energy solutions. The company offers a comprehensive range of services covering every stage of the nuclear fuel cycle, including reactor design, construction, and operational support. With a strong emphasis on safety and advanced technology, Orano is committed to supplying low-carbon power generation solutions. Additionally, it engages in renewable energy initiatives through partnerships aimed at developing high-tech solutions. As energy demand increases and the need for sustainable practices intensifies, Orano focuses on creating cleaner energy alternatives that contribute to reducing greenhouse gas emissions. The company aims to enhance transparency, coherence, and efficiency in its operations while preparing for the future energy landscape.

Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.

Endesa is an electric utility company headquartered in Madrid, Spain, that generates, distributes, and supplies electricity primarily in Spain and Portugal. Founded in 1944, the company has an installed generation capacity of 22 gigawatts, utilizing a diverse mix of energy sources, including hydroelectric, nuclear, coal, natural gas, oil, solar, and wind. Endesa serves approximately 11.2 million customers and employs over 10,000 people. In addition to its core electricity services, Endesa operates in the natural gas sector and provides energy-related services, emphasizing a commitment to sustainability and technological innovation to address current and future energy challenges. The company also supplies gas to retail and business customers in Spain and France.

SiPearl is a French semiconductor company established in 2019, headquartered in Maisons-Laffitte, Île-de-France, with research and development centers located in France, Germany, and Spain. The company specializes in the design of high-performance, low-power microprocessors intended for exascale supercomputers, aligning its product development with the European Union’s technological goals. Its first microprocessor range, Rhea, is set for commercialization in early 2024 and is based on the Arm Neoverse V1 architecture. SiPearl is committed to manufacturing Rhea using advanced processes from TSMC, ensuring state-of-the-art performance. The microprocessors are aimed at a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, serving scientific researchers and major players in the IT, electronics, and automotive sectors.

Reden Solar specializes in the development, financing, construction, and operation of solar photovoltaic power plants across Europe and Latin America. With an installed portfolio of 762 megawatts and an additional 15 gigawatts under development, the company primarily focuses on markets in France and Spain, while also expanding its operations in Greece and Italy. Reden Solar provides a variety of photovoltaic solutions, including agricultural greenhouses, ground-mounted systems, shelters, and rooftop installations, aimed at promoting sustainable energy production and contributing to environmental conservation.

Orange is a digital operator that offers mobile and internet services in Europe and Africa, and corporate telecommunication services worldwide. The group operates under the brand name Orange Business Services, both in France and internationally, in the business communication and IT services markets. Orange Business Services offers a range of services to large corporates, local authorities, and SMEs in France, as well as to multinationals around the world, supporting the implementation of their communication projects. To do so, OBS offers a full range of voice and data, IT, and integrated services. The Orange Fabs is an international network of startup drivers that provides startups in the digital space with advice, training, and events, as well as resources and expertise. Orange was founded in 1991 and is headquartered in Paris, France with a presence in 30 countries.

AB Science is a France-based pharmaceutical company founded in 2001 by a team of researchers, clinicians, and entrepreneurs. It specializes in the research, discovery, development, and marketing of protein kinase inhibitors, focusing on targeted therapies using tyrosine kinase inhibitors. The company aims to address significant unmet medical needs in various fields, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases. AB Science is committed to innovating and developing new drugs that can significantly improve the lives of patients and enhance treatment outcomes in both human and veterinary medicine.

Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

OVH APAC is a leading cloud provider known for its innovative and cost-effective solutions tailored for a diverse clientele, ranging from startups to large enterprises. Founded in 1999 by Octave Klaba and based in France, OVH offers a comprehensive portfolio of services, including web hosting, dedicated servers, cloud solutions, domain registration, and VOIP telephony. The company distinguishes itself through its proprietary global fiber-optic network and green data centers, which enable optimal performance and reliability. With a commitment to research and development and complete control over its supply chain, OVH delivers high-quality products and exceptional customer service. Additionally, OVH has established a strong partnership with VMware, integrating advanced software solutions to enhance network performance and streamline service delivery for its customers. As a result, OVH is recognized as one of the top internet hosting companies globally, serving millions of customers with cutting-edge technology and expertise.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in advanced machine vision sensors and systems through its innovative neuromorphic vision technology. Originally known as Chronocam SAS, the company rebranded in 2018 to reflect its pioneering approach to computer vision, which mimics the human eye and brain by detecting essential motion information rather than capturing a series of images. This unique Metavision® method enables Prophesee to achieve exceptional performance metrics, including high-speed time resolution, dynamic range, and significant reductions in data volume and power consumption. Its technology caters to a diverse range of industries, including biomedical, gaming, industrial automation, mobile devices, robotics, security, and automotive applications. Prophesee's team of over 100 engineers holds more than 50 international patents and has established a global presence with offices in cities such as Grenoble, Shanghai, Tokyo, and Silicon Valley, supported by a network of prominent investors.

Nomagic, Inc. is a company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce warehouses. By providing smart pick-and-place robotic systems, Nomagic enhances efficiency, flexibility, and reliability in the logistics process. Their technology automates repetitive tasks, reduces fulfillment costs, and addresses labor shortages, allowing warehouses to operate seamlessly around the clock. The company's robots have already been implemented on packing lines at Cdiscount, a leading French e-commerce platform. Utilizing artificial intelligence, Nomagic's systems continuously learn and adapt to changing conditions, improving the agility of warehouse operations and ensuring reliable delivery of goods.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Kayrros is a leading advanced data analytics company that specializes in providing actionable insights for the global energy market. With a team of over 100 employees from more than 15 nationalities, Kayrros operates from its headquarters in Paris and has additional offices in Houston, London, New York, and Singapore. The company integrates alternative and market data to create unique product offerings that enhance decision-making across the energy sector. Its platform focuses on environmental intelligence and asset observation, delivering critical insights related to greenhouse gas reduction, ecosystem protection, and energy transition management. Kayrros aims to support governments, companies, and investment markets in assessing the climate impact of energy and industrial activities, thereby enabling faster and more informed decisions. The company’s solutions are designed to be scalable and continuously expand to include new geographic regions and data sources, enhancing transparency in energy markets worldwide.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Bouygues Telecom is a prominent telecommunications operator in France, offering a wide range of services that include mobile, fixed-line, television, internet, and cloud computing. The company serves approximately 11.1 million mobile customers and 2.1 million fixed broadband customers, including over 1.5 million professional and corporate clients. Renowned for its innovative approach, Bouygues Telecom has introduced several pioneering products, such as the first unlimited call plans, fixed-mobile convergence offers for corporate customers, and the quadruple play solution known as ideo. The company also launched B&YOU, a web-only offer that revolutionized mobile telephony. With a mobile network that covers 99% of the population and a rapidly expanding 4G network, Bouygues Telecom is committed to enhancing customer experience through its dedicated team of over 9,000 employees and a robust customer service framework that includes 2,000 advisers and 2,500 sales staff. The company's focus on innovation and customer satisfaction positions it as a key player in the French telecommunications market.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Orange is a digital operator that offers mobile and internet services in Europe and Africa, and corporate telecommunication services worldwide. The group operates under the brand name Orange Business Services, both in France and internationally, in the business communication and IT services markets. Orange Business Services offers a range of services to large corporates, local authorities, and SMEs in France, as well as to multinationals around the world, supporting the implementation of their communication projects. To do so, OBS offers a full range of voice and data, IT, and integrated services. The Orange Fabs is an international network of startup drivers that provides startups in the digital space with advice, training, and events, as well as resources and expertise. Orange was founded in 1991 and is headquartered in Paris, France with a presence in 30 countries.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in advanced machine vision sensors and systems through its innovative neuromorphic vision technology. Originally known as Chronocam SAS, the company rebranded in 2018 to reflect its pioneering approach to computer vision, which mimics the human eye and brain by detecting essential motion information rather than capturing a series of images. This unique Metavision® method enables Prophesee to achieve exceptional performance metrics, including high-speed time resolution, dynamic range, and significant reductions in data volume and power consumption. Its technology caters to a diverse range of industries, including biomedical, gaming, industrial automation, mobile devices, robotics, security, and automotive applications. Prophesee's team of over 100 engineers holds more than 50 international patents and has established a global presence with offices in cities such as Grenoble, Shanghai, Tokyo, and Silicon Valley, supported by a network of prominent investors.

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Mobidiag is a Finnish-French biotechnology company that focuses on developing and marketing innovative molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. Utilizing established qPCR and microarray technologies, Mobidiag provides a wide array of fast, reliable, and cost-effective diagnostic tests and automated platforms suitable for laboratories of various sizes. Their offerings enable the detection of a broad spectrum of clinically relevant bacteria, parasites, viruses, and antibiotic resistance markers, thereby facilitating quicker diagnosis and treatment in hospitals, laboratories, and clinics.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

MotorK is a software as a service (SaaS) provider focused on the automotive retail industry in the EMEA region, employing over 400 staff across eleven offices in eight countries, including Italy, Spain, France, Germany, Portugal, the UK, Belgium, and Israel. The company specializes in developing digital sales and marketing solutions that enhance customer experience for car manufacturers and dealers. MotorK offers a comprehensive suite of integrated digital products and services, including platforms for traffic acquisition, inventory management, sales operations, and promotional campaigns. Key products include WebSparK, a web module known for its technical and design excellence, and StockSparK, a stock management tool that aggregates and enhances inventory visibility for potential buyers. With a strong emphasis on innovation, MotorK boasts one of the largest research and development teams in the European automotive digital sales and marketing sector.

Mobidiag is a Finnish-French biotechnology company that focuses on developing and marketing innovative molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. Utilizing established qPCR and microarray technologies, Mobidiag provides a wide array of fast, reliable, and cost-effective diagnostic tests and automated platforms suitable for laboratories of various sizes. Their offerings enable the detection of a broad spectrum of clinically relevant bacteria, parasites, viruses, and antibiotic resistance markers, thereby facilitating quicker diagnosis and treatment in hospitals, laboratories, and clinics.

NAVYA is a leading French name in the autonomous vehicle market and in smart shared mobility solutions. With more than 200 employees in France (Paris and Lyon) and in the United States (Michigan), NAVYA develops, manufactures and commercializes autonomous, driverless, and electric vehicles that combine robotic, digital and driving technologies at the highest level. Since 2015, NAVYA has been the first to market and put into service autonomous mobility solutions, shuttles and cabs. NAVYA has a range of two autonomous vehicles: the AUTONOM®SHUTTLE, launched in September 2015, of which more than 100 have already been produced as of today and 89 sold in 17 countries as of June 30, 2018, notably in the United States, France, Germany, Switzerland, Japan and Australia, and the AUTONOM®CAB, unveiled in November 2017 and whose first road tests will start shortly.

October is a pan-European lending platform that aims to empower businesses by simplifying access to funding. Founded in France in 2014 under the name Lendix, the company emerged following regulatory changes that disrupted traditional banking practices. With offices in France, Spain, Italy, and the Netherlands, October operates an online marketplace that connects private investors with enterprises of various sizes. This platform allows investors to finance businesses directly, offering fully disclosed terms and facilitating a streamlined investment process. Institutional lenders complement individual contributions, ensuring borrowers benefit from high success rates and quick processing times. October's mission is to democratize finance, providing a secure and efficient way for individuals to invest in the real economy.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Forsee Power SAS is a French company specializing in the design and manufacture of smart battery systems. Founded in 2007 and based in Ivry-sur-Seine, it focuses on providing innovative solutions for the electric transportation sector, including electric and hybrid vehicles, trams, and marine applications. Additionally, Forsee Power produces modular battery systems for portable and mobile equipment, as well as energy storage solutions. The company's products cater to various markets, supplying power to devices such as medical equipment, electric scooters, and robotics. With a commitment to innovation and operational excellence, Forsee Power aims to support a sustainable energy transition and enhance the lifecycle of smart mobility and connected devices.

SunPartner develops and commercializes innovative technologies adapted to communication, energy, transportation, and building needs. It offers Wysips Crystal, an ultra-thin and transparent photovoltaic material with an optical system designed for emissive screens for smartphones and smartwatches; Wysips Graphics masks solar cells for connected devices; Wysips Reflect that can be integrated into any kind of reflective screen; Wysips Cameleon for signs and billboard; and Light-Fidelity or Visible Light Communication, a communication technology that transmits data over visible light waves and has applications in location-based services, electromagnetic sensitive places, shopping 2.0, and smartCities. SunPartner is a France-based company that was founded in 2008.

Electro Power Systems (EPS) operates in the sustainable energy sector, focusing on hybrid-storage solutions and microgrids that convert intermittent renewable energy into reliable power sources. Headquartered in Paris, with research, development, and manufacturing facilities in Italy, EPS has developed innovative energy storage technologies protected by 125 patents and applications, built on over a decade of research and development. The company aims to stabilize electrical grids with high levels of renewable energy integration in developed nations and to provide affordable off-grid power solutions in emerging economies without relying on subsidies. EPS has successfully executed 36 large-scale projects, including off-grid hybrid systems powered by renewable energy and energy storage, totaling over 35 MW of installed power. These systems serve more than 165,000 customers daily and include an additional 18 MW of grid support systems, resulting in a total capacity output of 47 MWh across 21 countries, spanning Europe, Latin America, Asia, and Africa.

Mobidiag is a Finnish-French biotechnology company that focuses on developing and marketing innovative molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. Utilizing established qPCR and microarray technologies, Mobidiag provides a wide array of fast, reliable, and cost-effective diagnostic tests and automated platforms suitable for laboratories of various sizes. Their offerings enable the detection of a broad spectrum of clinically relevant bacteria, parasites, viruses, and antibiotic resistance markers, thereby facilitating quicker diagnosis and treatment in hospitals, laboratories, and clinics.